Summary & Overview
HCPCS J7527: Everolimus, Oral, 0.25 mg
HCPCS Level II code J7527 denotes Everolimus, oral, 0.25 mg — an oral mTOR inhibitor used in several clinical settings, including transplant immunosuppression and certain oncology indications. This nationally relevant drug code matters because it identifies the specific product and dose for billing and reimbursement, supports pharmacy and outpatient clinic claims, and enables payers and providers to track utilization and cost for specialty oral therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and what to expect in terms of payer coverage policy areas. The publication outlines common benchmarking topics such as reimbursement unitization for oral specialty drugs, prior authorization and medical necessity themes, and administrative billing considerations specific to HCPCS Level II drug codes.
The report provides operational detail useful to pharmacy managers, billing professionals, and policy analysts: how J7527 is used on claims for outpatient pharmacy or clinic dispensing, common payer policy levers that affect access, and areas where national policy updates or payer-specific rules commonly appear. Data not available in the input where specific utilization, modifiers, or associated ICD-10 diagnoses would be cited.
Billing Code Overview
HCPCS Level II code J7527 represents Everolimus, oral, 0.25 mg, a systemic oral immunosuppressant and mTOR inhibitor used in specified clinical indications. The service type is prescription oral medication administration/dispensing. The typical site of service is outpatient pharmacy dispensing or clinic-based medication management where oral specialty drugs are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
An adult patient with a solid-organ transplant (e.g., renal transplant) or certain advanced malignancies is prescribed oral everolimus for immunosuppression or targeted therapy. The prescription is written by a transplant physician, oncologist, or advanced practice provider following clinical consultation and required baseline labs (CBC, CMP, lipid panel) and therapeutic drug monitoring where indicated. The medication J7527 (everolimus, oral, 0.25 mg) is dispensed by an outpatient specialty pharmacy or clinic infusion/medication area for take-home oral administration. Typical workflow: visit and diagnosis established → baseline labs and medication screening (drug interactions, hepatic/renal function) → prior authorization obtained if required by payer → prescription written and coded as J7527 with appropriate modifier(s) to reflect billing circumstances → medication dispensed with counseling on dosing, adverse effects, and monitoring → follow-up visits include lab checks and dose adjustments recorded in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Original unmodified claim | Use when no modifier applies and the service is billed normally. |